Immutep
Immutep is a biotechnology company focused on developing LAG-3 related immunotherapy products for the treatment of cancer and autoimmune diseases. The company is pioneering the LAG-3 space and has clinical-stage assets targeting areas of high unmet need.
Short position
Immutep (ASX:IMM) has 1.07% of its shares on issue reported as short positions as of 5 Oct 2026, or about 15,826,532 shares. Over the past 30 days that figure has fallen 1.00 percentage points, and over 90 days it has fallen 1.38 percentage points. Its highest recorded short interest was 3.74% in July 2026. IMM is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Immutep (IMM) company profile
Profile, insiders and operations
Company
AI-generated research profile of Immutep
IMM intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links